Metastatic Urethral Urothelial Carcinoma Withdrawn Phase 2 Trials for Cyclophosphamide (DB00531)

IndicationStatusPhase
DBCOND0110111 (Metastatic Urethral Urothelial Carcinoma)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03935347Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based ChemotherapyTreatment